To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
GTCR-backed TerSera Therapeutics agrees to buy the Xermelo product from Lexicon Pharmaceuticals
TerSera Therapeutics agreed to buy the product for about $159 million plus a potential milestone payments based on development and commercialization of Xermelo.
